医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

A Novel Lectin Was Isolated by the Research Team of Jinchi Biotech Ltd. (JBL)

2014年10月27日 PM05:00
このエントリーをはてなブックマークに追加


 

ZHANGJIAJIE, China

Lately, Andrias Davidianus Lectin (ADL) was isolated successfully from the body-surface mucus of Andrias Davidianus (Giant Salamander) by JBL Research Team who had done 3 years of research on purification of a secreted lectin from Andrias Davidianus skin and its antibacterial activity. In August of 2014, the research paper of ADL-related research achievement was published in ‘Comparative Biochemistry and Physiology, Part C, DOI: 10.1016/j.cbpc.2014.08.008’.

ADL is very important to the body-surface immunity of Andrias Davidianus. ADL is a 17 kDa carbohydrate-binding protein, and it contains 2 identical 8.5 kDa subunits. The discovery and application of the lectin have great significance for Andrias Davidianus breeding and disease prevention.

Lectins are considered to be non enzymatic and non immune proteins or multivalent carbohydrate-binding protein, widely exist in animals (including amphibians), plants and microorganisms. Isolation and identification of lectins are particularly important in the study on pathogenesis process of microbial related.

ABOUT JINCHI

www.jc-biotech.com

Owning the world’s only Giant Salamander Museum, Jinchi Biotech Ltd. mainly specialized in the R&D of giant salamander related biotech products with more than 40 skincare and health products under two product lines, namely SHINIQUE and ANDRIAS. With strong scientific research background and a comprehensive business model, Jinchi Biotech Ltd. values virtue and goodwill, commits to deliver quality products to consumers, and devotes to the health, beauty and biomedical industries.

Disclaimer

The statements contained herein are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements.

CONTACT

Jinchi Biotech Ltd.
Chan Luo, +86-731-8979-2661
ir@jc-biotech.com

同じカテゴリーの記事 

  • 一份具有里程碑意义的报告证明,大量使用尼古丁不会导致健康问题高发
  • Modalis Therapeutics Reports Data Supporting Development of a Transformative Epigenome Editing Therapeutic, MDL-101: a First-in-Class Epigenome Editing approach for the Treatment of LAMA2-deficient congenital muscular dystrophy (LAMA2-CMD)
  • Galderma Receives Filing Acceptances for Nemolizumab in Prurigo Nodularis and Atopic Dermatitis in Four Additional Countries
  • Inocras Hong Kong Limited, in Collaboration with Cancerinformation.com.hk Charity Foundation and Sponsored by AstraZeneca Hong Kong, Offers Free BRCA or HRD Genetic Testing for Eligible Cancer Patients in Hong Kong and Macau
  • BrainChip Earns Australian Patent for Improved Spiking Neural Network